Efficacy of halobetasol and tazarotene lotion for plaque psoriasis utilizing IGAxBSA measurements

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Green, Lawrence J. ^{[2
]}

Bagel, Jerry ^{[3
]}

Lin, Tina ^{[4
]}

Martin, Gina ^{[5
]}

Israel, Robert ^{[5
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA

[3] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA

[4] Ortho Dermatol, Bridgewater, NJ USA

[5] Bausch Hlth, Bridgewater, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

9785

引用

页码：AB201 / AB201

页数：1

共 50 条

[31] Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study
Lebwohl, M. G.
Stein Gold, L.
Papp, K.
Han, G.
Pariser, D. M.
Lin, T.
Harris, S.
Jacobson, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : 1152 - 1160
[32] Real-world treatment outcomes with halobetasol propionate 0.01%/ tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
Vender, Ronald
Turchin, Irina
Lansang, Perla
Prajapati, Vimal H.
Legault, Mark
Barakat, Maxime
Yeung, Jensen
JAAD INTERNATIONAL, 2022, 8 : 60 - 63
[33] Safety and Efficacy of Halobetasol Propionate Lotion 0.01% in the Treatment of Moderate to Severe Plaque Psoriasis: A Pooled Analysis of 2 Phase 3 Studies
Sugarman, Jeffrey L.
Weiss, Jonathan S.
Tanghetti, Emil A.
Soung, Jennifer
Yamauchi, Paul S.
Lin, Tina
Harris, Susan
Martin, Gina
Pillai, Radhakrishnan
CUTIS, 2019, 103 (02): : 111 - +
[34] Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
Tyring, Stephen
Kircik, Leon H.
Yamauchi, Paul
Jacobson, Abby
Lin, Tina
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (04) : 389 - 396
[35] A polymeric emulsion of halobetasol propionate and tazarotene in the treatment of palmoplantar psoriasis
Campbell, Caroline R.
Babalola, Folawiyo O.
Yousif, Jenna E.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB10 - AB10
[36] Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination
Gold, Linda Stein
Kircik, Leon H.
Pariser, David
Sugarman, Jeffrey L.
Lin, Tina
Kang, Robert
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 863 - 868
[37] Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants
Cook-Bolden, Fran E.
Hebert, Adelaide A.
Guenthner, Scott T.
Kang, Robert
Martin, Gina
Jacobson, Abby
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 747 - 754
[38] Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials
Gold, Linda Stein
Lebwohl, Mark G.
Sugarman, Jeffrey L.
Pariser, David M.
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
Israel, Robert
Ramakrishna, Tage
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 287 - 293
[39] Successful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion
Shoen, Ezra
Hou, Angela
Zahn, Joseph
Friedman, Adam
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (03) : 336 - 337
[40] Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis
Lebwohl, Mark G.
Sugarman, Jeffrey L.
Gold, Linda Stein
Pariser, David M.
Lin, Tina
Pillai, Radhakrishnan
Martin, Gina
Harris, Susan
Israel, Robert
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 282 - 285

← 1 2 3 4 5 →